[go: up one dir, main page]

MXPA03008837A - Una composicion farmaceutica estable de pravastatina. - Google Patents

Una composicion farmaceutica estable de pravastatina.

Info

Publication number
MXPA03008837A
MXPA03008837A MXPA03008837A MXPA03008837A MXPA03008837A MX PA03008837 A MXPA03008837 A MX PA03008837A MX PA03008837 A MXPA03008837 A MX PA03008837A MX PA03008837 A MXPA03008837 A MX PA03008837A MX PA03008837 A MXPA03008837 A MX PA03008837A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pravastatin
stable pharmaceutical
relates
composition
Prior art date
Application number
MXPA03008837A
Other languages
English (en)
Inventor
Malik Rajiv
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of MXPA03008837A publication Critical patent/MXPA03008837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se relaciona a una composicion farmaceutica estable que comprende pravastatina o sus sales farmaceuticamente aceptables y un portador, que imparte un pH entre 6.5 y 8.5 a una dispersion acuosa de la composicion. La invencion tambien se relaciona a un proceso para elaborar la composicion farmaceutica.
MXPA03008837A 2001-03-27 2002-03-22 Una composicion farmaceutica estable de pravastatina. MXPA03008837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN375DE2001 2001-03-27
PCT/IB2002/000882 WO2002076376A2 (en) 2001-03-27 2002-03-22 A stable pharmaceutical composition of pravastatin

Publications (1)

Publication Number Publication Date
MXPA03008837A true MXPA03008837A (es) 2004-05-05

Family

ID=29560486

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008837A MXPA03008837A (es) 2001-03-27 2002-03-22 Una composicion farmaceutica estable de pravastatina.

Country Status (17)

Country Link
US (1) US20040157925A1 (es)
EP (1) EP1372616A4 (es)
JP (1) JP2004527518A (es)
KR (1) KR20030096294A (es)
CN (1) CN1240377C (es)
BR (1) BR0208504A (es)
CA (1) CA2442280A1 (es)
CZ (1) CZ20032828A3 (es)
EE (1) EE200300468A (es)
HU (1) HUP0401234A2 (es)
MX (1) MXPA03008837A (es)
NZ (1) NZ528543A (es)
PL (1) PL369268A1 (es)
RU (1) RU2003131338A (es)
SK (1) SK13022003A3 (es)
WO (1) WO2002076376A2 (es)
ZA (1) ZA200308256B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003055217A (ja) * 2001-08-10 2003-02-26 Taiyo Yakuhin Kogyo Kk 医薬組成物
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
DE60331963D1 (de) * 2003-08-06 2010-05-12 Galephar M F Stabile pharmazeutische zubereitungen zur kontrollierten freisetzung von fenofibrat and pravastatin
WO2006008757A2 (en) * 2004-05-05 2006-01-26 Cadila Healthcare Limited Stabilized pharmaceutical compositions of pravastatin
ATE549399T1 (de) * 2006-12-13 2012-03-15 Dsm Sinochem Pharm Nl Bv Verfahren zur herstellung von pravastatin
EP2170294A1 (en) * 2007-06-25 2010-04-07 Pharmathen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
WO2011049122A1 (ja) * 2009-10-21 2011-04-28 第一三共株式会社 プラバスタチンナトリウム口腔内速崩壊錠及びその製造方法
JP5988963B2 (ja) 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija

Also Published As

Publication number Publication date
HUP0401234A2 (hu) 2004-11-29
JP2004527518A (ja) 2004-09-09
EE200300468A (et) 2004-02-16
PL369268A1 (en) 2005-04-18
ZA200308256B (en) 2004-08-12
EP1372616A2 (en) 2004-01-02
SK13022003A3 (sk) 2004-03-02
NZ528543A (en) 2005-07-29
WO2002076376A3 (en) 2003-01-09
KR20030096294A (ko) 2003-12-24
CA2442280A1 (en) 2002-10-03
WO2002076376A2 (en) 2002-10-03
EP1372616A4 (en) 2004-06-23
CN1240377C (zh) 2006-02-08
CZ20032828A3 (en) 2004-07-14
BR0208504A (pt) 2004-03-09
US20040157925A1 (en) 2004-08-12
CN1518443A (zh) 2004-08-04
RU2003131338A (ru) 2005-02-10

Similar Documents

Publication Publication Date Title
AU5242000A (en) Nematicidal trifluorobutenes
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
AU3652102A (en) Compounds and their uses
YU83502A (sh) Nova farmaceutska smeša
WO2000055125A3 (en) N-cyanomethyl amides as protease inhibitors
YU84703A (sh) Oralni rastvor aripiprazola
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
YU73802A (sh) Postupak sinteze perindoprila i njegovih farmaceutski prihvatljivih soli
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
MXPA04003636A (es) Composiciones farmaceuticas que comprenden acido micofenolico o sal de micofenolato.
BG105009A (en) Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline
DE60112330D1 (en) Pyrazolopyridinderivate
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
BG106681A (en) Solutions containing epinastine
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
WO2002053519A3 (en) Hydrophobic polyamine analogs and methods for their use
BG105197A (en) Polymorph form of a medicament
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
MXPA03008837A (es) Una composicion farmaceutica estable de pravastatina.
WO2001087831A3 (en) Novel amorphous form of omeprazole salts
HRP20030002A2 (en) STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
MXPA04004937A (es) Proceso para preparar 3,3??,3,6??,-tetraalquil-2,2??-bifenoles y 3,??,6,??-tetraalquil-5,??-dihalo-2,??-bifenoles.
AP2001002369A0 (en) Pharmaceutical complex.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal